Literature DB >> 32060762

Met-PET uptake index for total tumor resection: identification of 11C-methionine uptake index as a goal for total tumor resection including infiltrating tumor cells in glioblastoma.

Akihiro Inoue1, Takanori Ohnishi2, Shohei Kohno3, Shiro Ohue4, Masahiro Nishikawa3, Satoshi Suehiro3, Shirabe Matsumoto3, Saya Ozaki3, Mana Fukushima5, Mie Kurata6, Riko Kitazawa5, Seiji Shigekawa3, Hideaki Watanabe3, Takeharu Kunieda3.   

Abstract

Glioblastoma multiforme (GBM) is largely due to glioma stem cells (GSCs) that escape from total resection of gadolinium (Gd)-enhanced tumor on MRI. The aim of this study is to identify the imaging requirements for maximum resection of GBM with infiltrating GSCs. We investigated the relationship of tumor imaging volume between MRI and 11C-methionine (Met)-PET and also the relationship between Met uptake index and tumor activity. In ten patients, tumor-to-contralateral normal brain tissue ratio (TNR) was calculated to evaluate metabolic activity of Met uptake areas which were divided into five subareas by the degrees of TNR. In each GBM, tumor tissue was obtained from subareas showing the positive Met uptake. Immunohistochemistry was performed to examine the tumor proliferative activity and existence of GSCs. In all patients, the volume of Met uptake area at TNR ≦ 1.4 was larger than that of the Gd-enhanced area. The Met uptake area at TNR 1.4 beyond the Gd-enhanced tumor was much wider in high invasiveness-type GBMs than in those of low invasiveness type, and survival was much shorter in the former than the latter types. Immunohistochemistry revealed the existence of GSCs in the area showing Met uptake at TNR 1.4 and no Gd enhancement. Areas at TNR > 1.4 included active tumor cells with relatively high Ki-67 labeling index. In addition, it was demonstrated that GSCs could exist beyond the border of Gd-enhanced tumor. Therefore, to obtain maximum resection of GBMs, including infiltrating GSCs, aggressive surgical excision that includes the Met-positive area at TNR 1.4 should be considered.

Entities:  

Keywords:  Glioblastoma; Methionine; Positron emission tomography; Surgical planning; Total resection

Mesh:

Substances:

Year:  2020        PMID: 32060762     DOI: 10.1007/s10143-020-01258-7

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  2 in total

1.  Quantitative volumetric analysis of primary glioblastoma multiforme on MRI and 11C-methionine PET: initial study on five patients.

Authors:  Jingwang Zhao; Zhijuan Chen; Li Cai; Shaoya Yin; Weidong Yang; Zengguang Wang
Journal:  Neurol Neurochir Pol       Date:  2019-03-11       Impact factor: 1.621

2.  Identification of a cancer stem cell in human brain tumors.

Authors:  Sheila K Singh; Ian D Clarke; Mizuhiko Terasaki; Victoria E Bonn; Cynthia Hawkins; Jeremy Squire; Peter B Dirks
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

  2 in total
  3 in total

1.  Quantitative measurement of peritumoral concentrations of glutamate, N-acetyl aspartate, and lactate on magnetic resonance spectroscopy predicts glioblastoma-related refractory epilepsy.

Authors:  Yawara Nakamura; Akihiro Inoue; Masahiro Nishikawa; Takanori Ohnishi; Hajime Yano; Yonehiro Kanemura; Yoshihiro Ohtsuka; Saya Ozaki; Kosuke Kusakabe; Satoshi Suehiro; Daisuke Yamashita; Seiji Shigekawa; Hideaki Watanabe; Riko Kitazawa; Junya Tanaka; Takeharu Kunieda
Journal:  Acta Neurochir (Wien)       Date:  2022-09-15       Impact factor: 2.816

2.  Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity.

Authors:  Takanori Ohnishi; Daisuke Yamashita; Akihiro Inoue; Satoshi Suehiro; Shiro Ohue; Takeharu Kunieda
Journal:  Brain Sci       Date:  2022-04-28

3.  CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.

Authors:  Masahiro Nishikawa; Akihiro Inoue; Takanori Ohnishi; Hajime Yano; Yonehiro Kanemura; Shohei Kohno; Shiro Ohue; Saya Ozaki; Shirabe Matsumoto; Satoshi Suehiro; Yawara Nakamura; Seiji Shigekawa; Hideaki Watanabe; Riko Kitazawa; Junya Tanaka; Takeharu Kunieda
Journal:  Cancer Med       Date:  2021-02-05       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.